Natrii Iodidum [131i] Ge Healthcare (Sodium Iodide (131i))

After oral ingestion, Sodium Iodide (131i) is absorbed and selectively taken up by thyroid cells via the sodium‑iodide symporter. The iodine‑131 isotope then emits beta radiation that either creates images for diagnostic purposes or destroys overactive or malignant thyroid cells while limiting exposure to surrounding tissues.

The prescribed dose of Natrii Iodidum [131i] is determined by the treating physician based on the specific clinical indication, patient weight, thyroid uptake studies, and therapeutic goals. Dosing is individualized and should follow the prescriber's instructions and relevant regulatory guidelines.

Use of radioactive iodine during pregnancy is generally avoided because it can cross the placenta and affect fetal thyroid development. It is also contraindicated while breastfeeding, as iodine can be secreted in breast milk and expose the infant to radiation. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with non‑radioactive therapies such as antithyroid drugs or surgical removal, Natrii Iodidum [131i] offers a non‑invasive option that can both diagnose and treat thyroid conditions in a single administration. It provides targeted radiation, reducing the need for repeated procedures, but requires careful patient selection and radiation safety measures.

The product should be stored at ambient temperature, below 25 °C, in its original sealed container. It must be protected from light, moisture, and any sources of contamination. Handling should follow standard radiopharmaceutical safety protocols, including use of shielding and personal protective equipment where appropriate.

Natrii Iodidum [131i] is administered orally as a single dose. The patient swallows the preparation with water, and subsequent imaging or therapeutic monitoring is performed according to the clinical protocol. No intravenous or intramuscular injection is required for this formulation.

The most serious risks include severe hypothyroidism, radiation thyroiditis, and bone marrow suppression leading to pancytopenia. Rarely, allergic reactions or pulmonary fibrosis may occur. Patients should be monitored closely for signs of these complications, and appropriate medical intervention should be initiated promptly.

Individuals who are pregnant, breastfeeding, have uncontrolled thyroid disorders, severe renal impairment, or known hypersensitivity to iodine should avoid using Natrii Iodidum [131i]. Additionally, patients currently taking antithyroid medications or lithium should not receive the product without appropriate medical guidance.